These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16894565)

  • 1. Molecular determinants of irinotecan efficacy.
    Vallböhmer D; Iqbal S; Yang DY; Rhodes KE; Zhang W; Gordon M; Fazzone W; Schultheis AM; Sherrod AE; Danenberg KD; Lenz HJ
    Int J Cancer; 2006 Nov; 119(10):2435-42. PubMed ID: 16894565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
    Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
    Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
    Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of cetuximab efficacy.
    Vallböhmer D; Zhang W; Gordon M; Yang DY; Yun J; Press OA; Rhodes KE; Sherrod AE; Iqbal S; Danenberg KD; Groshen S; Lenz HJ
    J Clin Oncol; 2005 May; 23(15):3536-44. PubMed ID: 15908664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
    Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
    Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
    Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
    Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
    Matsubara J; Nishina T; Yamada Y; Moriwaki T; Shimoda T; Kajiwara T; Nakajima TE; Kato K; Hamaguchi T; Shimada Y; Okayama Y; Oka T; Shirao K
    Br J Cancer; 2008 Feb; 98(4):832-9. PubMed ID: 18231104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
    Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F
    Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
    Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
    Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
    Gustavsson B; Kaiser C; Carlsson G; Wettergren Y; Odin E; Lindskog EB; Niyikiza C; Ma D
    Int J Cancer; 2009 Mar; 124(5):1220-6. PubMed ID: 19051292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
    Ceppi P; Longo M; Volante M; Novello S; Cappia S; Bacillo E; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
    J Thorac Oncol; 2008 Jun; 3(6):583-9. PubMed ID: 18520795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
    Ishida H; Shirakawa K; Ohsawa T; Hayashi Y; Okada N; Nakada H; Yokoyama M
    Gan To Kagaku Ryoho; 2005 Sep; 32(9):1295-9. PubMed ID: 16184927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.